A.R.T. Advisors’s Cymabay Therapeutics CBAY Stock Holding History

A.R.T. Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-195,480	Closed	-$383K	–	1090
2019 Q4	$383K	Buy	195,480 +153,541	+366%	+$577K	0.02%	945
2019 Q3	$215K	Sell	41,939 -42,500	-50%	-$257K	0.01%	1167
2019 Q2	$605K	Buy	84,439 +28,923	+52%	+$328K	0.03%	673
2019 Q1	$737K	Buy	55,516 +43,300	+354%	+$461K	0.04%	590
2018 Q4	$96K	Sell	12,216 -43,599	-78%	-$415K	0.01%	1170
2018 Q3	$618K	Buy	+55,815	New	+$693K	0.03%	762
2018 Q2	–	Sell	-57,631	Closed	-$748K	–	1829
2018 Q1	$748K	Buy	57,631 +42,400	+278%	+$527K	0.03%	777
2017 Q4	$140K	Buy	+15,231	New	+$130K	0.01%	1220
2015 Q3	–	Sell	-36,069	Closed	-$97K	–	1660
2015 Q2	$97K	Buy	36,069 +20,940	+138%	+$86K	﹤0.01%	1370
2015 Q1	$104K	Buy	+15,129	New	+$145K	﹤0.01%	1315

Other funds holding CBAY

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

A.R.T. Advisors's CBAY Position: Q1 2020 in Review

A.R.T. Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2020, closing a stake of 195,480 shares — an estimated $383K sold.

A.R.T. Advisors first reported a position in CBAY in Q1 2015 and held it in 10 quarters. The position peaked at $748K in Q1 2018. 102 funds tracked by Wall St. Rank hold CBAY as of Q1 2020.

A.R.T. Advisors reported no remaining Cymabay Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 195,480 Cymabay Therapeutics shares in Q1 2020, an estimated $383K.
A.R.T. Advisors first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 10 quarters.
A.R.T. Advisors's Cymabay Therapeutics position peaked at $748K in Q1 2018.
102 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.